GAIN for loss: adalimumab for infliximab-refractory Crohn disease

Ann Intern Med. 2007 Jun 19;146(12):888-90. doi: 10.7326/0003-4819-146-12-200706190-00011.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Crohn Disease / drug therapy*
  • Humans
  • Infliximab
  • Remission Induction
  • Treatment Failure
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab